Lilly To Pay Up To $500 Million In Second Zyprexa Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
The settlement resolves suits alleging Lilly inadequately warned patients of the risks of diabetes and hyperglycemia associated with the antipsychotic.